SecBot SecBot
PRESS-RELEASE ·Filed May 7, 2026

DNLI

Denali Therapeutics Inc.
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

Monitor initial AVLAYAH sales trajectory and payer coverage decisions over the next 2 quarters; key pipeline catalysts include DNL593 data (end 2026) and DNL126 BLA filing (2027). The strong cash position and royalty funding reduce near-term dilution risk.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$19.62
T+0 close · May 7, 2026 · via day close
Latest settled
+23.19%
T+60 · $24.17
Vs SPY
+18.35%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 8 $19.62entry
  2. T+1 · 6mo ago +0.25%α +0.02% · $19.67
  3. T+5 · 6mo ago −1.17%α −2.64% · $19.39
  4. T+20 · 5mo ago −0.51%α −0.53% · $19.52
  5. T+60 · 3mo ago +23.19%α +18.35% · $24.17
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Denali reported Q1 2026 EPS of -$0.69, a slight beat vs consensus -$0.71, but the headline is the FDA approval and U.S. launch of AVLAYAH (tividenofusp alfa) for Hunter syndrome, the first medicine to cross the blood-brain barrier via transferrin receptor. The company also secured $200M in royalty financing and has a robust pipeline with key readouts expected by end of 2026.

Key Financial Metrics

EPS
−$0.69
est −$0.71 · +2.8%
Rating
beat

Key Facts

  • FDA accelerated approval of AVLAYAH (tividenofusp alfa) for Hunter syndrome on March 25, 2026
  • First commercial patients dosed in April 2026; launch operational with payers engaged
  • Received $200M gross proceeds from Royalty Pharma synthetic royalty funding agreement
  • Cash, cash equivalents and marketable securities of $1.05B as of March 31, 2026
  • Net loss improved to $128.4M from $133.0M year-over-year
  • Pipeline progress: DNL126 (Sanfilippo) Phase 3 prep underway, DNL593 (FTD-GRN) data by end 2026, DNL628 (Alzheimer's) Phase 1b dosed

Financial Impact

AVLAYAH revenue potential uncertain but platform validation and $200M non-dilutive funding strengthen balance sheet; net loss slightly narrowed to $128.4M

revenuecashnet loss

Risk Factors

  • AVLAYAH commercial adoption and reimbursement uncertainty in Hunter syndrome market
  • Confirmatory trial (COMPASS) may affect continued approval
  • Pipeline setbacks could outweigh commercial progress
  • Takeda's termination of DNL593 collaboration adds development risk

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (25 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3290512

Track record

17 reports on DNLI

Performance horizon

2 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +7.03% at T+60 after the Mar 25, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $18.75 Now $18.08 −3.55% settles Nov 17
  2. Nov 3, 202613d ago 8-K Bullish 6/10 No price data
  3. Nov 3, 202613d ago Press Release Neutral 5/10 Entry $20.96 to $19.72 Now $18.08 −13.74% ▼ −5.92% −1.51% vs SPY
  4. Oct 30, 202617d ago Press Release Neutral 3/10 Entry $18.94 to $18.86 Now $18.08 −4.54% ▼ −0.42% +0.06% vs SPY
  5. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $18.66 Now $18.08 −3.11% No price data
  6. Sep 9, 20269w ago Insider Cluster Neutral 2/10 Entry $21.40 to $21.09 Now $18.08 −15.51% ▼ −1.45% −2.30% vs SPY
  7. Sep 4, 202610w ago Insider Cluster Neutral 2/10 Entry $22.08 to $21.57 Now $18.08 −18.12% ▼ −2.31% −1.84% vs SPY
  8. Aug 6, 202614w ago 8-K Mixed 6/10 Entry $24.83 to $25.00 Now $18.08 −27.18% ▲ +0.68% +0.71% vs SPY
  9. Jul 27, 202616w ago Press Release Neutral 1/10 Entry $24.05 Now $18.08 −24.82% No price data
  10. Jun 18, 202621w ago 8-K Bullish 6/10 Entry $23.31 to $24.05 Now $18.08 −22.44% ▲ +3.17% +3.49% vs SPY
Showing 10 of 17

US Market Status

Market Closed · Opens Wed (11h 19m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 7, 2026